Somavert

Description

Somavert is intended for the treatment of patients with acromegaly who have not responded adequately to surgery and/or radiation therapy and in whom therapy with somatostatin analogues has not normalized IGF-1 levels, or in cases of intolerance to this group of drugs.

Pegvisomant binds to growth hormone receptors on the cell surface and blocks their interaction with endogenous STH, disrupting signal transmission into the cell. Pegvisomant is highly selective for growth hormone receptors and does not interact with receptors for other cytokines, including prolactin. Suppression of growth hormone action under the influence of pegvisomant leads to a decrease in the concentration of IGF-1 in the blood serum, as well as serum proteins sensitive to growth hormone, including free IGF-1, the acid-labile subunit of IGF-1, and IGF-binding protein-3.

Active ingredient: pegvisomant

Storage temperature 2-8 degrees

Prescription drug